0000899243-19-004866.txt : 20190226
0000899243-19-004866.hdr.sgml : 20190226
20190226160652
ACCESSION NUMBER: 0000899243-19-004866
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190222
FILED AS OF DATE: 20190226
DATE AS OF CHANGE: 20190226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sheehy Douglas T.
CENTRAL INDEX KEY: 0001488637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 19633414
MAIL ADDRESS:
STREET 1: C/O AIMMUNE THERAPEUTICS, INC.
STREET 2: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-22
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001488637
Sheehy Douglas T.
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
See Remarks
Common Stock, $0.0001 par value
2019-02-22
4
A
0
12500
0.00
A
45668
D
Stock Option (right to buy)
23.72
2019-02-22
4
A
0
75000
0.00
A
2029-02-22
Common Stock
75000
75000
D
These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 32,500 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 89 shares acquired on November 15, 2018 pursuant to Issuer's employee stock purchase plan.
The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
General Counsel and Corporate Secretary
/s/ Douglas T. Sheehy
2019-02-26